Current developments in HIV chemotherapy

D. Christopher Meadows, Jacquelyn Gervay-Hague

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

HIV infection is the leading cause of death worldwide and despite major advances in treatment, more new cases were diagnosed in 2004 than any previous year. Current treatment regimens are based on the use of two or more drugs from two or more classes of inhibitors termed highly active antiretroviral therapy (HAART). Although HAART is capable of suppressing viral loads to undetectable levels, problems of toxicity, patient adherence, and particularly the emergence of drug-resistant viruses continues to spur the development of new chemotherapeutics to combat HIV. Clinical candidates from the four existing classes of inhibitors are presented in this review along with lead compounds against new viral targets, with special emphasis on HIV integrase.

Original languageEnglish (US)
Pages (from-to)16-29
Number of pages14
JournalChemMedChem
Volume1
Issue number1
DOIs
StatePublished - Jan 2006

Fingerprint

Chemotherapy
Highly Active Antiretroviral Therapy
HIV Integrase
HIV
Lead compounds
Drug Therapy
Patient Compliance
Viral Load
Viruses
Pharmaceutical Preparations
HIV Infections
Toxicity
Cause of Death
Therapeutics

Keywords

  • Antiviral agents
  • Drug design
  • Medicinal chemistry
  • Nucleosides
  • Viruses

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Organic Chemistry
  • Molecular Medicine

Cite this

Current developments in HIV chemotherapy. / Meadows, D. Christopher; Gervay-Hague, Jacquelyn.

In: ChemMedChem, Vol. 1, No. 1, 01.2006, p. 16-29.

Research output: Contribution to journalArticle

Meadows, D. Christopher ; Gervay-Hague, Jacquelyn. / Current developments in HIV chemotherapy. In: ChemMedChem. 2006 ; Vol. 1, No. 1. pp. 16-29.
@article{050002a5bc024afa90d604c0aad9379a,
title = "Current developments in HIV chemotherapy",
abstract = "HIV infection is the leading cause of death worldwide and despite major advances in treatment, more new cases were diagnosed in 2004 than any previous year. Current treatment regimens are based on the use of two or more drugs from two or more classes of inhibitors termed highly active antiretroviral therapy (HAART). Although HAART is capable of suppressing viral loads to undetectable levels, problems of toxicity, patient adherence, and particularly the emergence of drug-resistant viruses continues to spur the development of new chemotherapeutics to combat HIV. Clinical candidates from the four existing classes of inhibitors are presented in this review along with lead compounds against new viral targets, with special emphasis on HIV integrase.",
keywords = "Antiviral agents, Drug design, Medicinal chemistry, Nucleosides, Viruses",
author = "Meadows, {D. Christopher} and Jacquelyn Gervay-Hague",
year = "2006",
month = "1",
doi = "10.1002/cmdc.200500026",
language = "English (US)",
volume = "1",
pages = "16--29",
journal = "ChemMedChem",
issn = "1860-7179",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Current developments in HIV chemotherapy

AU - Meadows, D. Christopher

AU - Gervay-Hague, Jacquelyn

PY - 2006/1

Y1 - 2006/1

N2 - HIV infection is the leading cause of death worldwide and despite major advances in treatment, more new cases were diagnosed in 2004 than any previous year. Current treatment regimens are based on the use of two or more drugs from two or more classes of inhibitors termed highly active antiretroviral therapy (HAART). Although HAART is capable of suppressing viral loads to undetectable levels, problems of toxicity, patient adherence, and particularly the emergence of drug-resistant viruses continues to spur the development of new chemotherapeutics to combat HIV. Clinical candidates from the four existing classes of inhibitors are presented in this review along with lead compounds against new viral targets, with special emphasis on HIV integrase.

AB - HIV infection is the leading cause of death worldwide and despite major advances in treatment, more new cases were diagnosed in 2004 than any previous year. Current treatment regimens are based on the use of two or more drugs from two or more classes of inhibitors termed highly active antiretroviral therapy (HAART). Although HAART is capable of suppressing viral loads to undetectable levels, problems of toxicity, patient adherence, and particularly the emergence of drug-resistant viruses continues to spur the development of new chemotherapeutics to combat HIV. Clinical candidates from the four existing classes of inhibitors are presented in this review along with lead compounds against new viral targets, with special emphasis on HIV integrase.

KW - Antiviral agents

KW - Drug design

KW - Medicinal chemistry

KW - Nucleosides

KW - Viruses

UR - http://www.scopus.com/inward/record.url?scp=33646848691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646848691&partnerID=8YFLogxK

U2 - 10.1002/cmdc.200500026

DO - 10.1002/cmdc.200500026

M3 - Article

VL - 1

SP - 16

EP - 29

JO - ChemMedChem

JF - ChemMedChem

SN - 1860-7179

IS - 1

ER -